Performance and longevity supplement line launched by Jupiter Neurosciences

Nugevia, a new line of performance and longevity supplements from clinical-stage pharmaceutical company Jupiter Neurosciences, Inc., has been launched commercially. The first three formulations are intended for mitochondrial support, mental clarity, and beauty-from-within, which are anticipated to be sold direct-to-consumer in the third quarter of 2025. The line feature what the company called "intelligent stacking" of synergistic compounds that are designed to support cellular resilience and blood-brain barrier delivery.

“The launch of Nugevia is the natural next step in translating our science into broad, real-world impact,” stated Christer Rosén, chairman and CEO of Jupiter Neurosciences, in a June 9 press release¹. “By building on the same proprietary technology platform that underpins our prescription drug development, we’re delivering a differentiated consumer offering with unmatched bioavailability and scientific credibility.”

Earlier this year, Jupiter Neurosciences and phyto-technology manufacturer Aquanova announced² a joint effort to develop a line of supplement products, collaborating for eight years in the development of Jotrol, an orally administered resveratrol formulation in micellar form. The new products are supported by Jotrol, which has been part of therapeutic programs in Parkinson’s disease and Alzheimer’s. As noted in the press release, a Phase I clinical study published in the Journal of Alzheimer’s Disease and AAPS Open³ in February 2022 demonstrated the bioavailability of Jotrol, and Jupiter Neurosciences is moving toward a Phase IIa trial for Parkinson’s disease.

Also noted are the challenges with dosing – doses over 2 grams of resveratrol have shown gastrointestinal side effects, though the delivery platform has allowed its absorption without these side effects (1,2).

“We cracked the code on resveratrol's widely published issue with bioavailability, and now we’re unlocking its potential beyond the clinic,” added Rosén. “Consumers are seeking longevity solutions that are both credible and effective. Nugevia meets that demand.”

The launch of the supplement line is anticipated to generate revenue to support ongoing clinical trials for central nervous system therapies.

“Nugevia represents more than a product launch—it’s a strategic engine for growth,” stated Rosén. “By leveraging our core science in a consumer format, we’re creating a near-term revenue stream that supports our therapeutic pipeline and strengthens long-term shareholder value. It’s smart capital allocation with real scientific impact.”

References

1. Jupiter Neurosciences. Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science https://www.globenewswire.com/news-release/2025/06/09/3095732/0/en/Jupiter-Neurosciences-Launches-Nugevia-A-Premium-Longevity-and-Performance-Supplement-Line-Grounded-in-Clinical-Science.html (accessed 2025-06-11).
2. Krawiec, S. Jupiter Neurosciences and Aquanova to develop supplements that target aging as part of new strategic agreement https://www.nutritionaloutlook.com/view/jupiter-neurosciences-and-aquanova-to-develop-supplements-that-target-aging-as-part-of-new-strategic-agreement (accessed 2025-06-11).
3. Kemper, C.; Behnam, D.; Brothers, S. Wahlestedt, C.; Volmar, C-H,; Bennett, D.; Hayard, M.. Safety and pharmacokinetics of a highly bioavailable resveratrol preparation (JOTROL ^TM), AAPS Open, 2022. 8(11). DOI: 10.1186/s41120-022-00058-1